Life begins when a single cell develops into tissues, muscles, bones, and organs that give rise to different body parts. Stem cell research promises to be of potential help to people living with body damaging diseases such as cancer, diabetes, heart diseases, and many others. ESC has the capacity to eliminate or lessen these life-threatening diseases, thereby helping people in need. However, stem cell research has also been marred with ethical controversies. Critics argue that the side effects of ESC defeat its benefits. This research will evaluate various research studies with the aim of ascertaining how ESC can be used to grow body parts for people in need. In addition, the research will be argumentative that is, it will provide arguments for and against ESC.
Stem cells have the potential to help millions of people suffering from different diseases. To date, scientists have been able to discover improved treatment regimens for multiple numbers of diseases. This has increased the survival rate of cancer and diabetic patients. At least ESC has helped to increase the survival of cancer and diabetes patients. What patients prefer is nothing more than living a life free of suffering due to their health conditions.
The general objective of the study will be to investigate how embryonic stem cells can be used to grow body parts for people in need. The benefits of using ESC to grow body parts, successes of stem cell therapies, and the ethical considerations of ESC will be the specific objectives of my research.
Justification of the study
The research will be justified by the fact that millions of people die from cancer, diabetes, and many other diseases despite improved treatment regimes. This research will evaluate how embryonic stem cells can be used to reverse or control this problem.
Arguments for embryonic stem cells
The research will provide arguments for the use of ESC through the review of stem cell peer-reviewed articles. Some researchers have successfully used ESC to develop treatment regimens that have helped a number of patients. For instance, Schuurhuis et al. (2013) and Yong et al. (2013) argue that stem cell research can be used to control, eliminate, or reduce the effects of cancer and diabetes. These two articles demonstrate how ESC is capable of creating treatment regimes that are more effective than the current regimes.
Arguments against stem cell research
The research will extensively evaluate the sources of stem cell research controversies. In addition, some critics argue that embryonic stem cells can cause tumors and malignant carcinomas. For example, Friedman, Cassady, Beierle, Markert, and Gillespie (2012) argue that the current stem cell therapies are incapable of controlling cancer. They propose the use of virotherapy for cancer treatment. On the other hand, the article by Hunt (2008) will be used to evaluate and highlight the stem cell ethical controversies.
The research will use secondary sources to provide the arguments for and against ESC. Peer-reviewed journals, academic web articles, and books will be used to provide the required information. In addition, the research will use newspapers and other stem cell periodicals to collect more information. The findings, conclusion, and recommendation for further research will be presented through a well-written well-written research report.
Friedman, G. K., Cassady, K. A., Beierle, E. A., Markert, J. M., & Gillespie, G. Y. (2012). Targeting pediatric cancer stem cells with oncolytic virotherapy. Pediatric research, 71(4), 500-510.
Hunt, S., Y. (2008). Controversies in Treatment Approaches: Gene Therapy, IVF, Stem Cells, and Pharmacogenomics. Nature Education, 1(1), 221-222.
Schuurhuis, G. J., Meel, M. H., Wouters, F., Min, L. A., Terwijn, M., De Jonge, N. A., &… Smit, L. (2013). Normal Hematopoietic Stem Cells within the AML Bone Marrow Have a Distinct and Higher ALDH Activity Level than Co-Existing Leukemic Stem Cells. Plos ONE, 8(11), 1-15.
Yang, Z., Zhaoshun, J., Tingbao, Z., Mingliang, Y., Chengjin, H., Huimin, Z., &… Heng, L. (2013). Targeting insulin resistance in type 2 diabetes via immune modulation of cord blood-derived multipotent stem cells (CB-SCs) in stem cell educator therapy: phase I/II clinical trial. BMC Medicine, 11(1), 1-13.